Immunex ( IMNX) received Food and Drug Administration approval to market Novantrone as a treatment for certain forms of multiple sclerosis.

Novantrone is currently marketed, in combination with corticosteroids, to treat pain in patients with advanced hormone-refractory prostate cancer and for an initial therapy of acute nonlymphocytic leukemia.

The FDA approval allows Immunex to promote Novantrone as a treatment for secondary progressive multiple sclerosis.

Shares of Immunex recently traded up $1.25, or 3.3%, to $38.88 in Nasdaq in midday trading.

If you liked this article you might like

Durable Goods Orders Fall; Jobless Claims Tick Higher

Durable Goods Orders Fall; Jobless Claims Tick Higher

Tire-Kickers Like What They See in Auto Dealers

Tire-Kickers Like What They See in Auto Dealers

Retailers' Choice Words Turn Heads

Retailers' Choice Words Turn Heads

Consumer Hangs Around for Holidays

Consumer Hangs Around for Holidays

The Night Watch: Ariba Keeps Partying

The Night Watch: Ariba Keeps Partying